Detalhe da pesquisa
1.
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex.
Mol Cell
; 84(11): 2070-2086.e20, 2024 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38703770
2.
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.
Nature
; 567(7749): 545-549, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30894746
3.
TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.
Int J Mol Sci
; 19(3)2018 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29498681
4.
Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Int J Cancer
; 132(3): E106-15, 2013 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22907398
5.
LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
EMBO Mol Med
; 15(8): e18014, 2023 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37435859
6.
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
J Antimicrob Chemother
; 66(4): 802-12, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-21393174
7.
Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma.
Nat Cancer
; 2(3): 312-326, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33768209
8.
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers.
Cancer Res
; 81(7): 1627-1632, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33509943
9.
Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.
Cell Rep
; 21(12): 3483-3497, 2017 Dec 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29262328
10.
Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma.
Oncoimmunology
; 5(5): e1131378, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-27467948